---
title: 'Functional status and quality of life in older patients with advanced esophageal
  squamous cell cancer receiving second-line nivolumab ± ipilimumab therapy: A post
  hoc analysis of the phase 2, multicenter RAMONA study'
date: '2024-08-03'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39097500/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240804182128&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: 'INTRODUCTION: The phase 2 RAMONA study demonstrated that second-line
  nivolumab ± ipilimumab immunotherapy was feasible and effective in older patients
  with advanced esophageal squamous cell cancer (ESCC). Here, we presented results
  from functional status (FS) and quality-of-life (QoL) ...'
disable_comments: true
---
INTRODUCTION: The phase 2 RAMONA study demonstrated that second-line nivolumab ± ipilimumab immunotherapy was feasible and effective in older patients with advanced esophageal squamous cell cancer (ESCC). Here, we presented results from functional status (FS) and quality-of-life (QoL) ...